Aug 22, 2012|
What is fuelling the FMCG rally?
Even as economic uncertainty continues to loom, the FMCG sector remains a darling of the stock-market. The BSEFMCG index currently commands steep valuations of 47 times its trailing 12 months (TTM) earnings ending June 2012. In contrast, the broad market represented by SENSEX is trading at 23 times its TTM earnings.
One Rupee test on FMCG companies (standalone)
As more investors flock to the FMCG sector as a defensive measure, FMCG stocks continue to reap huge investment returns. Blue-chip stocks like Hindustan Unilever (HUL), Nestle, Dabur, Colgate, Britannia and Glaxo SmithKline Consumer yielded over ten-fold jump in return for every rupee invested (One rupee test) during the period FY10-FY12. Clearly, the FMCG sector is being lapped up by the investor community.
Warren Buffet, the guru of value investing believed that the best way to test the investment potential of a stock is to determine the return earned by shareholders on every rupee invested. In other words, have these stocks generated at least one rupee for every rupee invested? This is measured by the increase in market cap relative to the increase in net worth.
The table below shows that FMCG companies have done very well with the "one rupee test", which is why investors are willing to wager on this defensive bet?
Source: Ace Equity
||Increase in networth in Rs m (A)
||Increase in Market Cap in Rs m (B)
||Value created for every Re 1 invested (B/A)
|Glaxo Smithkline Consumer*
* Results follow calendar year
A critical evaluation of the table also shows that post 2010, the returns fetched on most FMCG stocks have declined in comparison to returns earned during the 2005-10 period. Dabur, Godrej Consumer and Marico have been in an expansion mode and as a result their value appreciation has been modest.
However, Glaxo SmithKline Consumer posted a steep jump in the "one rupee test" value in the FY10-FY12 period, and has been an exception in being higher than that for the FY05-FY10 period. FMCG behemoth, HUL, has continued to fetch over 40 times higher return for every rupee invested. The company has witnessed robust rise in its topline, and strong earnings growth since FY10. This has been the result of the return of pricing power and the company's renewed focus on the high margin personal care segment.
Another reason that the FMCG sector may be high in terms of value created is that market perception itself may be driving more and more investors to this industry viewed as "defensive". In this context, Benjamin Graham points out that the return earned on the stock of a company is a sum total of the real return, rate of inflation, and the return based on the market perception.
FMCG companies have been clocking double-digit sales growth despite price hikes. There does not seem to be any meaningful slowdown in consumption patterns. This pricing power has enabled them to maintain, and in some cases, even improve their profitability. Firm interest rates, high inflation and government policy paralysis do not seem to have affected the FMCG sector. At the same time, other sectors such as automobile, capital goods, power, infrastructure, realty and banking have been reeling under the challenging conditions.
And this weakness in other sectors has in turn further added to the charm of investing in the FMCG industry.
In our next article, we shall discuss whether the FMCG sector still holds steam or has sector peaked and is ripe for a correction.
||Madhu Gupta (Research Analyst), Managing Editor, ResearchPro has a post graduate degree in both physics and finance. Having worked with India's leading economic research agency, she has a natural flair for numbers and analytics. She brings with her a near-decade long rich experience in the field of finance. A firm believer of the principles of value investing, she looks for robust businesses with durable competitive advantages. Madhu contributes towards our small cap service Hidden Treasure.
More Views on News
Aug 9, 2017
While GST implementation brought down volumes and profitability in the short run, Marico remains optimistic in the long run.
Dec 9, 2016
Procter & Gamble Hygiene and Health Care has announced the first quarter results of the financial year ended June 2017 (1QFY17). The company's sales rose by 12.5%YoY while net profit rose by 50.1% YoY during the quarter.
Nov 30, 2016
Nestle India declared results for the quarter ended September 2016. Here is our analysis of the result.
Nov 30, 2016
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
Nov 28, 2016
Marico has reported a flat topline while the bottomline has grown by 18% YoY during the quarter.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407